AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14753482 — intervention group
Group type: COMPARATOR
Intervention: Initial Conservative Treatment
Number of subjects: 985
Study 10879362 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction using a kaleidoscope
Number of subjects: 384
Study 10879362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no distraction)
Number of subjects: 384
Study 8856385 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant cooling
Number of subjects: 63
Study 8856385 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory gasp test
Number of subjects: 63
Study 2045530 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (0.7 mg/kg for young, 1.2 mg/kg for elderly)
Number of subjects: 0
Study 2045530 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 2045530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6861601 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital 5 mg/kg/day for 5 to 12 months
Number of subjects: 74
Study 6861601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 6861601 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation in both groups
Number of subjects: 74
Study 30106335 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening dentifrice containing blue covarine (group CU)
Number of subjects: 60
Study 30106335 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional whitening dentifrice (group CW)
Number of subjects: 60
Study 30106335 — intervention group
Group type: COMPARATOR
Intervention: Regular dentifrice (group C)
Number of subjects: 60
Study 29768147 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol used as needed (200 μg of budesonide and 6 μg of formoterol)
Number of subjects: 4176
Study 29768147 — intervention group
Group type: COMPARATOR
Intervention: Budesonide maintenance therapy (200 μg of budesonide plus terbutaline 0.5 mg used as needed)
Number of subjects: 4176
Study 29768147 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol used as needed
Number of subjects: 4176
Study 29768147 — intervention group
Group type: COMPARATOR
Intervention: Budesonide maintenance therapy
Number of subjects: 4176
Study 27001560 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 120
Study 27001560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed exercises
Number of subjects: 120
Study 27001560 — intervention group
Group type: COMPARATOR
Intervention: Control (routine treatment and care)
Number of subjects: 120
Study 24907403 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/day)
Number of subjects: 377
Study 24907403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 23157902 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel alone (group A)
Number of subjects: 50
Study 23157902 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel combined with warfarin (group B)
Number of subjects: 50
Study 23157902 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical limb ischemia subgroup analysis (group A)
Number of subjects: 50
Study 23157902 — intervention group
Group type: COMPARATOR
Intervention: Critical limb ischemia subgroup analysis (group B)
Number of subjects: 50
Study 20947571 — intervention group
Group type: EXPERIMENTAL
Intervention: PhD algorithm for detecting HF events
Number of subjects: 214
Study 17106432 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1800 mg daily
Number of subjects: 76
Study 17106432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 11420479 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrothermal device for sutureless closed hemorrhoidectomy
Number of subjects: 80
Study 11420479 — intervention group
Group type: COMPARATOR
Intervention: Conventional open Milligan‐Morgan hemorrhoidectomy
Number of subjects: 80
Study 9192239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation using CO2 at -60 degrees C for 120 sec (group A)
Number of subjects: 20
Study 9192239 — intervention group
Group type: COMPARATOR
Intervention: No cryoablation (group B)
Number of subjects: 20
Study 8516491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 34
Study 3826269 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mechanics instruction
Number of subjects: 30
Study 3826269 — intervention group
Group type: COMPARATOR
Intervention: No instruction (Control)
Number of subjects: 30
Study 30340476 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of Dependence Scale for Khat (SDS-Khat)
Number of subjects: 178
Study 28039085 — intervention group
Group type: EXPERIMENTAL
Intervention: Active infrared laser stimulation to the lateral prefrontal cortex
Number of subjects: 118
Study 28039085 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) stimulation
Number of subjects: 118
Study 26231133 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized physical examination including carotid Doppler ultrasonography, echocardiography, electrocardiography, blood pressure monitoring, pulse rate, urine analysis, body mass index analysis, and laboratory tests.
Number of subjects: 77
Study 23997137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) of the foot for at least six hours daily under a plaster cast for two weeks
Number of subjects: 26
Study 23997137 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 26
Study 23997137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) of the foot
Number of subjects: 26
Study 23997137 — intervention group
Group type: EXPERIMENTAL
Intervention: Malfunction of IPC
Number of subjects: 26
Study 21159527 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (SET)
Number of subjects: 304
Study 21159527 — intervention group
Group type: COMPARATOR
Intervention: Go home and walk advice (WA)
Number of subjects: 304
Study 18348595 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Number of subjects: 23
Study 18348595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17726216 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative adjustable suture technique
Number of subjects: 88
Study 17726216 — intervention group
Group type: COMPARATOR
Intervention: Fixed conventional suture technique
Number of subjects: 88
Study 12703846 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring stretches (3 bouts of 20 seconds)
Number of subjects: 32
Study 12703846 — intervention group
Group type: COMPARATOR
Intervention: Rest (no stretching)
Number of subjects: 32
Study 12703846 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch condition
Number of subjects: 32
Study 12703846 — intervention group
Group type: COMPARATOR
Intervention: Non-stretch condition
Number of subjects: 32
Study 12703846 — intervention group
Group type: EXPERIMENTAL
Intervention: Females (irrespective of stretch condition)
Number of subjects: 32
Study 10763937 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful H. pylori eradication (63 patients, 72%)
Number of subjects: 87
Study 10763937 — intervention group
Group type: COMPARATOR
Intervention: Failed H. pylori eradication (24 patients, 28%)
Number of subjects: 87
Study 8878342 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg, acute dose)
Number of subjects: 8
Study 8878342 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day for 14 days, chronic dose)
Number of subjects: 8
Study 8878342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1447078 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volume of fluid (LF)
Number of subjects: 8
Study 1447078 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate volume of fluid (MF)
Number of subjects: 8
Study 1447078 — intervention group
Group type: EXPERIMENTAL
Intervention: Small volume of fluid (SF)
Number of subjects: 8
Study 1447078 — intervention group
Group type: COMPARATOR
Intervention: No fluid (NF)
Number of subjects: 8
Study 29627346 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% SSB price increase
Number of subjects: 2020
Study 29627346 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% SSB price increase
Number of subjects: 2020
Study 29627346 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational poster exposure
Number of subjects: 2020
Study 27741345 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole topical solution (10%)
Number of subjects: 0
Study 24038028 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of corticosteroid
Number of subjects: 0
Study 24038028 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoter variations in intrinsic apoptosis genes
Number of subjects: 0
Study 22647787 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 322
Study 22647787 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 322
Study 22647787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Metoprolol and Carvedilol
Number of subjects: 322
Study 20028946 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and glucose infusion (euglycemic-hyperinsulinemic clamp)
Number of subjects: 6
Study 20028946 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and glucose infusion plus Intralipid and heparin infusion
Number of subjects: 6
Study 20028946 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 6
Study 17985382 — intervention group
Group type: EXPERIMENTAL
Intervention: Export-Medtronic (EM)
Number of subjects: 103
Study 17985382 — intervention group
Group type: COMPARATOR
Intervention: Diver-Invatec (DI)
Number of subjects: 103
Study 17010005 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil monotherapy (25-75 mg/day)
Number of subjects: 101
Study 17010005 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (25-75 mg/day of naftopidil and 10-20 mg/day of propiverine hydrochloride or 2-6 mg/day of oxybutynin hydrochloride)
Number of subjects: 101
Study 17010005 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 101
Study 12705171 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% azelastine eye drops, twice daily
Number of subjects: 116
Study 12705171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 10632236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (up to 200 mg/d)
Number of subjects: 166
Study 10632236 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (up to 300 mg/d)
Number of subjects: 166
Study 8719717 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine ultrasound examination during gestational week 18 with additional information on alternatives (early abdominal ultrasound, both routine ultrasound and amniocentesis).
Number of subjects: 2412
Study 8719717 — intervention group
Group type: COMPARATOR
Intervention: Standard information provided at control antenatal clinics.
Number of subjects: 2412
Study 1330434 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-40 mg/day lovastatin
Number of subjects: 919
Study 1330434 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day (minidose) warfarin
Number of subjects: 919
Study 1330434 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 20-40 mg/day lovastatin and 1 mg/day warfarin
Number of subjects: 919
Study 1330434 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin placebo
Number of subjects: 919
Study 1330434 — intervention group
Group type: COMPARATOR
Intervention: Warfarin placebo
Number of subjects: 919
Study 1330434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose (81 mg/day) aspirin
Number of subjects: 919
Study 2983630 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg/kg)
Number of subjects: 38
Study 31476901 — intervention group
Group type: EXPERIMENTAL
Intervention: AVS-guided adrenalectomy
Number of subjects: 1625
Study 31476901 — intervention group
Group type: COMPARATOR
Intervention: Non AVS-guided adrenalectomy
Number of subjects: 1625
Study 31476901 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 1625
Study 29800048 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% rapamycin
Number of subjects: 179
Study 29800048 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% rapamycin
Number of subjects: 179
Study 29800048 — intervention group
Group type: COMPARATOR
Intervention: Vehicle only
Number of subjects: 179
Study 27281542 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (diet and exercise)
Number of subjects: 32
Study 25262260 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak CK-MB concentration
Number of subjects: 1799
Study 25262260 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the time-concentration curve (AUC)
Number of subjects: 1799
Study 25262260 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC
Number of subjects: 1799
Study 22241144 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen for 15 min
Number of subjects: 38
Study 22241144 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 38
Study 22241144 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 38
Study 19243753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination hormone therapy (HT), 5 microg ethinyl E(2) and 1 mg norethindrone acetate for 4 weeks
Number of subjects: 10
Study 19243753 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 10
Study 18498416 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg group (muffin containing one egg)
Number of subjects: 32
Study 18498416 — intervention group
Group type: COMPARATOR
Intervention: Control group (egg-free muffin)
Number of subjects: 32
Study 15819765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 15 microg (F)
Number of subjects: 99
Study 15819765 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 0.25 mg (D)
Number of subjects: 99
Study 15819765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 15 microg plus diamorphine 0.25 mg (FD)
Number of subjects: 99
Study 11899505 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin infusion
Number of subjects: 0
Study 11899505 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin infusion with large-volume paracentesis
Number of subjects: 0
Study 11899505 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin infusion in selected patients
Number of subjects: 0
Study 11899505 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin infusion with vasopressin analogue
Number of subjects: 0
Study 10980827 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) as a marker of sub-clinical atherosclerosis and cardiovascular risk
Number of subjects: 0
Study 10980827 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary preventive therapies (statin drugs and aspirin)
Number of subjects: 0
Study 7669490 — intervention group
Group type: COMPARATOR
Intervention: R 56865 (20 mg)
Number of subjects: 12
Study 7669490 — intervention group
Group type: COMPARATOR
Intervention: R 56865 (30 mg)
Number of subjects: 12
Study 7669490 — intervention group
Group type: COMPARATOR
Intervention: R 56865 (40 mg)
Number of subjects: 12
Study 7669490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2288834 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of eltoprazine (8 mg)
Number of subjects: 12
Study 2288834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of eltoprazine (3 mg)
Number of subjects: 12
Study 2288834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of eltoprazine (8 mg)
Number of subjects: 12
Study 7026073 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus mastectomy (surgery)
Number of subjects: 132
Study 7026073 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus radiotherapy
Number of subjects: 132
Study 7026073 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (chemotherapy plus mastectomy and chemotherapy plus radiotherapy)
Number of subjects: 132
Study 7026073 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 132
Study 7026073 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group (chemotherapy plus mastectomy)
Number of subjects: 132
Study 7026073 — intervention group
Group type: COMPARATOR
Intervention: Surgery versus radiotherapy
Number of subjects: 132
Study 31460627 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction scale for outpatient care users (ESCOMA)
Number of subjects: 13814
Study 31460627 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis (CFA) model
Number of subjects: 13814
Study 31460627 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement invariance analysis
Number of subjects: 13814
Study 31460627 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability assessment using McDonald's Omega Coefficient (ω)
Number of subjects: 13814
Study 28705314 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus palliative care intervention (UC + PAL)
Number of subjects: 150
Study 28705314 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 150
Study 25319251 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP-based selection (n=47)
Number of subjects: 776
Study 25319251 — intervention group
Group type: COMPARATOR
Intervention: MRI-based selection (n=16)
Number of subjects: 776
Study 25319251 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP acquisition/processing
Number of subjects: 776
Study 25319251 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatch classification
Number of subjects: 776
Study 25319251 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP acquisition time
Number of subjects: 776
Study 25319251 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID processing time
Number of subjects: 776
Study 23407100 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 461
Study 21078950 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-100480 at 600 mg twice daily for 28 days
Number of subjects: 0
Study 21078950 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-100480 with pyrazinamide on days 27 and 28
Number of subjects: 0
Study 21078950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21078950 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid at 300 mg daily for 4 days
Number of subjects: 0
Study 19377083 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarity Therapy (PT)
Number of subjects: 42
Study 19377083 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Respite Control (ERC)
Number of subjects: 42
Study 17680858 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 80
Study 17680858 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 80
Study 16391480 — intervention group
Group type: EXPERIMENTAL
Intervention: Geowave device in geopathic zone
Number of subjects: 52
Study 16391480 — intervention group
Group type: EXPERIMENTAL
Intervention: Geowave device in neutral zone
Number of subjects: 52
Study 16391480 — intervention group
Group type: COMPARATOR
Intervention: Geopathic zone without Geowave device
Number of subjects: 52
Study 16391480 — intervention group
Group type: COMPARATOR
Intervention: Neutral zone without Geowave device
Number of subjects: 52
Study 12014063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg OD for 3 weeks followed by randomization to fexofenadine or placebo for another 3 weeks
Number of subjects: 21
Study 12014063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10221688 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimegestone (various doses) with micronized oestradiol (2 mg/day)
Number of subjects: 203
Study 8536299 — intervention group
Group type: COMPARATOR
Intervention: Migraineurs without aura
Number of subjects: 75
Study 8536299 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 75
Study 8536299 — intervention group
Group type: COMPARATOR
Intervention: Migraineurs with aura
Number of subjects: 75
Study 2344316 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar tap method
Number of subjects: 110
Study 2344316 — intervention group
Group type: COMPARATOR
Intervention: Tendon tap method
Number of subjects: 110
Study 2344316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 110
Study 7405974 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microgram estrogen
Number of subjects: 32
Study 7405974 — intervention group
Group type: COMPARATOR
Intervention: 20 microgram estrogen
Number of subjects: 32
Study 31688930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-salt pod system (NSPS)
Number of subjects: 90
Study 31688930 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 90
Study 31688930 — intervention group
Group type: COMPARATOR
Intervention: Cigarette abstinence
Number of subjects: 90
Study 27981744 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced stretching intervention with individual phone counseling and SMS support for 12 weeks, followed by acculturation workshops for weeks 13-24
Number of subjects: 80
Study 27981744 — intervention group
Group type: COMPARATOR
Intervention: Standard stretching intervention, structured 6 min stretching exercise program for at least three times per day and 5 days per week
Number of subjects: 80
Study 27981744 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced stretching intervention
Number of subjects: 80
Study 27981744 — intervention group
Group type: COMPARATOR
Intervention: Standard stretching intervention
Number of subjects: 80
Study 25266608 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise
Number of subjects: 40
Study 25266608 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 40
Study 25266608 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity exercise
Number of subjects: 40
Study 25266608 — intervention group
Group type: COMPARATOR
Intervention: Vigorous-intensity exercise vs Light-intensity exercise
Number of subjects: 40
Study 25266608 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (all intensities)
Number of subjects: 40